Pari passu dimers of dimers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 33, 2012, Pages 13140-13141

  Sliwkowski, Mark X ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PERJETA; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

BINDING SITE; BREAST CANCER; CANCER SURVIVAL; CRYSTAL STRUCTURE; DIMERIZATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; LIGAND BINDING; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION;

HUMANS; PROTEIN MULTIMERIZATION; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 84865191071     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1209959109     Document Type: Note

References (16)

1. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137. (Pubitemid 33674041)
2. Burgess AW, et al. (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541-552. (Pubitemid 37222478)
3. Liu P, et al. (2012) A single ligand is sufficient to activate EGFR dimers. Proc Natl Acad Sci USA 109:10861-10866.
4. Cho HS, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760.
5. Garrett TP, et al. (2003) The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11:495-505. (Pubitemid 36293841)
6. Tzahar E, et al. (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5267-5287.
7. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL, 3rd (1994) Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91:8132-8136.
8. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA (2010) ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 107:7692-7697.
9. Zhang Q, Park E, Kani K, Landgraf R (2012) Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. Proc Natl Acad Sci USA 109:13237-13242.
10. Chen CH, Chernis GA, Hoang VQ, Landgraf R (2003) Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci USA 100:9226-9231. (Pubitemid 37033911)
11. Park E, Baron R, Landgraf R (2008) Higher-order association states of cellular ERBB3 probed with photocross- linkable aptamers. Biochemistry 47:11992-12005.
12. Franklin MC, et al. (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328. (Pubitemid 38482068)
13. Agus DB, et al. (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137. (Pubitemid 41039113)
14. Baselga J, et al.; CLEOPATRA Study Group (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119.
15. Scheuer W, et al. (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69:9330-9336.
16. Junttila TT, et al. (2009) Ligand-independent HER2/- HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440.